Advanced search
Publication Cover
Journal of Enzyme Inhibition and Medicinal Chemistry Volume 37, 2022 - Issue 1
Submit an article Journal homepage
1,595
Views
0
CrossRef citations to date
0
Altmetric
Research Papers

Design, synthesis, and biological evaluation of arylmethylpiperidines as Kv1.5 potassium channel inhibitors

Lingyue Zhaoa Jiang Su Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing, China;b Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, ChinaView further author information
,
Qian Yanga Jiang Su Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing, China;b Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, ChinaView further author information
,
Yiqun Tangc Department of Clinical Pharmacy, School of Basic Medical Sciences and Clinical Pharmacy, China Pharmaceutical University, Nanjing, ChinaView further author information
,
Qidong Youa Jiang Su Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing, China;b Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, ChinaCorrespondence[email protected]
View further author information
&
Xiaoke Guoa Jiang Su Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing, China;b Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, ChinaCorrespondence[email protected]
View further author information
Pages 462-471 | Received 09 Sep 2021, Accepted 09 Dec 2021, Published online: 10 Jan 2022

References

  • Burashnikov A, Antzelevitch C. Can inhibition of IKur promote atrial fibrillation? Heart Rhythm 2008;5:1304–9.
  • Mulder BA, Schnabel RB, Rienstra M. Predicting the future in patients with atrial fibrillation: who develops heart failure? Eur J Heart Fail 2013;15:366–7.
  • Nattel S, Carlsson L. Innovative approaches to anti-arrhythmic drug therapy. Nat Rev Drug Discov 2006;5:1034–49.
  • Wolf PA, Mitchell JB, Baker CS, et al. Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch Intern Med 1998;158:229–34.
  • Brandt MC, Priebe L, Bohle T, et al. The ultrarapid and the transient outward K+ current in human atrial fibrillation. Their possible role in postoperative atrial fibrillation. J Mol Cell Cardiol 2000;32:1885–96.
  • Brunner M, Kodirov SA, Mitchell GF, et al. In vivo gene transfer of Kv1.5 normalizes action potential duration and shortens QT interval in mice with long QT phenotype. AM J Physiol Heart Circ Physiol 2003;285:H194–H203.
  • Yang Y, Li J, Lin X, et al. Novel KCNA5 loss-of-function mutations responsible for atrial fibrillation. J Hum Genet 2009;54:277–83.
  • Olson TM, Alekseev AE, Liu XK, et al. Kv1.5 channelopathy due to KCNA5 loss-of-function mutation causes human atrial fibrillation. Hum Mol Genet 2006;15:2185–91.
  • Wang YJ, Chen BS, Lin MW, et al. Time-dependent block of ultrarapid-delayed rectifier K+ currents by aconitine, a potent cardiotoxin, in heart-derived H9c2 myoblasts and in neonatal rat ventricular myocytes. Toxicol Sci 2008;106:454–63.
  • Nerbonne JM, Kass RS. Molecular physiology of cardiac repolarization. Physiol Rev 2005;85:1205–53.
  • Martens JR, Kwak YG, Tamkun MM. Modulation of Kv channel alpha/beta subunit interactions. Trends Cardiovas Med 1999;9:253–8.
  • Tanabe Y, Hatada K, Naito N, et al. Over-expression of Kv1.5 in rat cardiomyocytes extremely shortens the duration of the action potential and causes rapid excitation. Biochem Biophys Res Commun 2006;345:1116–21.
  • Wu SD, Fluxe A, Sheffer J, et al. Discovery and in vitro/in vivo studies of tetrazole derivatives as Kv1.5 blockers. Bioorg Med Chem Lett 2006;16:6213–8.
  • Griffin A, Scott RH. Properties of K+ currents recorded from cultured ovine trachea submucosal gland-cells. Resp Physiol 1994;96:297–309.
  • Rettig J, Heinemann SH, Wunder F, et al. Inactivation properties of voltage-gated K+ channels altered by presence of beta-subunit. Nature 1994;369:289–94.
  • Starkus JG, Schlief T, Rayner MD, Heinemann SH. Unilateral exposure of Shaker B potassium channels to hyperosmolar solutions. Biophys J 1995;69:860–72.
  • England SK, Uebele VN, Kodali J, et al. A Novel K+ Channel beta-subunit (hKv beta 1.3) is produced via alternative mRNA splicing. J Biol Chem 1995;270:28531–4.
  • England SK, Uebele VN, Shear H, et al. Characterization of a voltage-gated K+ channel beta subunit expressed in human heart. Proc Natl Acad Sci USA 1995;92:6309–13.
  • Tamargo J, Caballero R, Gómez R, Delpón E. I(Kur)/Kv1.5 channel blockers for the treatment of atrial fibrillation. Expert Opin Investig Drugs 2009;18:399–416.
  • Fedida D. Vernakalant (RSD1235): a novel, atrial-selective antifibrillatory agent. Expert Opin Investig Drugs 2007;16:519–32.
  • Wettwer E, Hála O, Christ T, et al. Role of IKur in controlling action potential shape and contractility in the human atrium – influence of chronic atrial fibrillation. Circulation 2004;110:2299–306.
  • Fedida D, Orth PMR, Chen JYC, et al. The mechanism of atrial antiarrhythmic action of RSD1235. J Cardiovasc Electrophysiol 2005;16:1227–38.
  • Fedida D, Eldstrom J, Hesketh JC, et al. Kv1.5 is an important component of repolarizing K + current in canine atrial myocytes. Circ Res 2003;93:744–51.
  • Brendel J, Peukert S. Blockers of the Kv1.5 channel for the treatment of atrial arrhythmias. Expert Opin Ther Pat 2002;12:1589–98,
  • Guo X, Chen CL, Yang Q, et al. Effects of a novel class III antiarrhythmic agent, CPUY11018, on rat atrial fibrillation. Drug Develop Res 2010;71:303–12.
  • Chodoeva A, Bosc JJ, Guillon J, et al. 8-O-Azeloyl-14-benzoylaconine: a new alkaloid from the roots of Aconitum karacolicum Rapcs and its antiproliferative activities. Bioorg Med Chem 2005;13:6493–501.
  • Tai YT, But PPH, Young K, Lau CP. Cardiotoxicity after accidental herb-induced aconite poisoning. Lancet 1992;340:1254–6.
  • Fu M, Li RX, Fan L, et al. Sarcoplasmic reticulum Ca2+ release channel ryanodine receptor (RyR2) plays a crucial role in aconitine-induced arrhythmias. Biochem Pharmacol 2008;75:2147–56.
  • Bartosova L, Novak F, Bebarova M, et al. Antiarrhythmic effect of newly synthesized compound 44Bu on model of aconitine-induced arrhythmia – compared to lidocaine. Eur J Pharmacol 2007;575:127–33.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.